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Abstract
Background/Aims—The aim of this study was to explore the association of a functional
YKL-40 promoter polymorphism (rs4950928) with baseline disease stage, response to antiviral
therapy, and risk of liver disease progression in a group of patients with chronic hepatitis C
(CHC).
Address all correspondence to: Robert J. Fontana, MD, Professor of Internal Medicine, University of Michigan Medical Center, Ann
Arbor, MI 48109-0362, Tel: (734)-936-4780, Fax: (734)-936-7392, rfontana@med.umich.edu.
*The HALT-C Trial was registered with clinicaltrials.gov (#NCT00006164).
This is publication #74 of the HALT-C Trial.
Statement of Interests
Financial relationships of the authors with Hoffmann-La Roche, Inc. (now Genentech), are as follows: R. J. Fontana was previously on
the speaker’s bureau; R. K. Sterlingis a consultant and receives research support; A. S. Lok is a consultant and receives research
support. Authors with no financial relationships related to this project are: H. J. Litman, J. L. Dienstag, H. L. Bonkovsky, and G. L.
Su.
In addition, many of the HALT-C Trial investigators have other associations with industry relating to the area of hepatitis C, and, to
achieve the highest level of disclosure, we list these as well.
R. J. Fontana: Consultant: Bristol-Myers Squibb; Consultant: Abbott Pharmaceuticals, Bayer/Siemens, GlaxoSmithKline.
J. L. Dienstag: Research Support: Vertex Pharmaceuticals; Serves on Data Monitoring Committee: Schering-Plough Research
Institute, Human Genome Sciences, and Medtronic; Ad hoc Hepatitis Advisory Board: Boehringer-Ingelheim; Antiviral Advisory
Board: Gilead Sciences; Ad hoc Consultant (stock options): Achillion; Clinical Advisory Board (stock options): Nucleonics; Scientific
Advisory Board (stock options): Metabasis.
H. L. Bonkovsky: Consultant: Boehringer-Ingelheim; Consultant/Advisory Board/Research Support: Clinuvel, Inc.; Consultant/
Advisory Board/Research Support: Novartis Pharmaceuticals; Consultant/Speakers’ Bureau: Lundbeck Pharmaceuticals; Research
Support: Vertex Pharmaceuticals. American Porphyria Foundation, Member of Scientific Advisory Board; Consultant; Receives
research and educational support. Iron Disorders Institute, Chair, Scientific Advisory Board; Consultant.
R. K. Sterling: Consultant and research support: Schering-Plough (now Merck); Research support: GlaxoSmithKline; Consultant:
Vertex Pharmaceuticals; Consultant: Salix; Consultant and Research support: Bayer; Research support: Pfizer; Research support:
Medtronic.
A. S. Lok: Research Support: Merck; Eisai Pharmaceuticals; Bristol-Myers Squibb. Consultant: Abbott.
NIH Public Access
Author Manuscript
Liver Int. Author manuscript; available in PMC 2013 April 1.
Published in final edited form as:
Liver Int. 2012 April ; 32(4): 665–674. doi:10.1111/j.1478-3231.2011.02686.x.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Methods—YKL-40 promoter polymorphisms were determined in 456 HALT-C Trial patients
with bridging fibrosis or cirrhosis entering a prerandomization lead-in peginterferon/ribavirin 24-
week treatment phase and in 462 patients followed for a mean of 3.8 years after randomization to
maintenance peginterferon or observation.
RESULTS—Mean patient age was 49.5 years, 70.4% were male, and 71.2% were Caucasian. The
17% frequency of the YKL-40 minor allele (T) was similar to that reported in the general
population. YKL-40 genotype was associated significantly with baseline serum YKL-40 levels but
was not associated with the likelihood of a virological response following 24 to 48 weeks of
peginterferon/ribavirin therapy. Serum YKL-40 levels remained significantly lower during follow-
up in the randomized TT homozygotes compared to CT heterozygotes and CC homozygotes (p
<0.001). Despite this association, YKL-40 genotype was not associated with the risk of clinical or
histologic liver disease progression.
CONCLUSIONS—A reduced frequency of the protective YKL-40 promoter polymorphism was
not observed in the HALT-C Trial patient population. The absence of an association between
YKL-40 promoter polymorphisms and baseline liver-disease severity as well as with the risk of
liver-disease progression over time suggests that this polymorphism is not associated with disease
progression in CHC patients with established fibrosis.
Keywords
cirrhosis; decompensation; genetic polymorphisms; hepatitis C; interferon; virological response
Introduction
YKL-40 is a fibroblast growth factor that contributes to the remodeling of inflamed tissues
such as human liver and synovia via the degradation of low-density extracellular matrix (1–
4). Secreted by activated macrophages, YKL-40 is believed to act as a chemoattractant for
endothelial cells, can modulate angiogenesis during tissue repair, and is expressed in
multiple tissues including human liver (5,6). The serum level of YKL-40 has been evaluated
as a noninvasive marker of various chronic inflammatory and fibrotic liver diseases,
including alcoholic liver disease and chronic hepatitis C (CHC) (1, 7,8). The strong
correlation between serum YKL-40 levels and hepatic mRNA levels in patients with CHC
suggests that serum YKL-40 levels, in part, reflect ongoing hepatic fibrogenesis (1). In
addition, among patients with CHC, serial measurement of serum YKL-40 levels can
differentiate patients with slow from those with rapid progression of liver fibrosis (1).
Genetic polymorphisms in the CHI3L1 gene located on chromosome 1q32.1 that encodes
for YKL-40 were described recently (9,10). In particular, a functional upstream promoter
polymorphism of CHI3L1 (rs4950928) has been associated with reduced serum levels of
YKL-40 in multiple independent patient cohorts and with a reduced risk of asthma and
bronchial hyperresponsiveness (10). In addition, the presence of this functional
polymorphism in a large cohort of German patients with CHC was associated with a lower
stage of liver fibrosis as well as lower serum YKL-40 levels (11).
The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was a
prospective multicenter study of maintenance peginterferon in patients with CHC and
advanced fibrosis who failed to respond to prior interferon-based treatment (12). During a
24-week lead-in phase, all patients were retreated with full-dose peginterferon alfa-2a and
ribavirin (13). Patients with HCV RNA detectable at week 20 were categorized as
nonresponders and were eligible for randomization, whereas week-20 virologic responders
continued combination treatment for a full 48 weeks in the “responder” arm of the trial
(Figure 1). Recently, in 513 HALT-C Trial patients participating in an ancillary study of
serum fibrosis markers, we demonstrated that serum YKL-40 levels were associated
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strongly with the stage of hepatic fibrosis (14). In addition, lower baseline serum YKL-40
levels were associated independently with a higher likelihood of achieving a week-20
virological response during the lead-in phase (15). Furthermore, serum YKL-40 levels
during treatment helped distinguish patients who went on to achieve a sustained virological
response (SVR) from those who experienced virologic breakthrough or relapse. Finally, a
multivariate model that included baseline serum YKL-40 levels was the best predictor of
clinical outcomes in 462 patients followed for a median of 3.8 years in the randomized
phase of the HALT-C Trial (16).
The aim of the current study was to determine the relationship between YKL-40 promoter
polymorphisms at rs4950928 and baseline serum YKL-40 levels in the HALT-C Trial
patients who were enrolled in the serum fibrosis marker ancillary study. Anticipating that
the YKL-40 promoter polymorphism T minor allele would be associated with lower serum
YKL-40 levels, we also sought to determine whether this genetic polymorphism was
associated with the likelihood of a virological response during the lead-in phase of the study.
Finally, we evaluated the relationship between YKL-40 polymorphisms and the risk of
clinical and histological disease progression in 462 subjects followed in the randomized
phase of the trial.
Materials & Methods
Eligible HALT-C Trial subjects had detectable serum HCV RNA and bridging hepatic
fibrosis (i.e., Ishak fibrosis score ≥3) or cirrhosis on a pretreatment liver biopsy and
documented failure to achieve a SVR to a prior course of interferon with or without
ribavirin; all subjects had clinically compensated liver disease at entry (12, 13). Subjects
were retreated with full-dose peginterferon-α2a, 180 μg per week, and ribavirin, 1.0 to 1.2
grams per day, for 24 weeks in the “lead-in phase” of the study. Subjects who remained
viremic at treatment week 20 met the definition of nonresponse and were eligible for
randomization to maintenance peginterferon-α2a, 90 μg per week, versus no treatment for
3.5 years; subjects with undetectable HCV RNA at week 20, as determined by polymerase
chain reaction (PCR) assay (Roche Molecular Systems, COBAS Amplicor v 2.0, sensitivity
of 100 IU/ml), were categorized as responders, were not eligible for randomization, but
continued in the “responder arm” of the trial and completed 48 weeks of full-dose (as
tolerated) combination antiviral treatment. All HALT-C Trial participants entering the lead-
in and randomized phase at four of the 10 HALT-C Trial clinical sites—the University of
Michigan, University of Massachusetts/University of Connecticut, Massachusetts General
Hospital, and the Virginia Commonwealth University—were eligible for the serum fibrosis
marker ancillary study and had additional serum and DNA collected; samples were frozen
immediately at −80° C and stored at a central repository (Seracare, Gaithersberg, MD). The
study was approved by local Institutional Review Boards, and all patients provided written
informed consent for both the main trial and this ancillary study, including specific consent
for genetic testing.
Laboratory and clinical assessment during the randomized phase
Routine baseline laboratory values (e.g., serum AST, ALT, albumin, bilirubin, platelet
count) were obtained at local hospital laboratories. A baseline liver biopsy obtained within
12 months of enrollment was scored by consensus among a group of hepatopathologists for
the degree of hepatic fibrosis and inflammation defined by the Ishak scoring system, and the
degree of hepatic steatosis was estimated as grade 0 to 4 (17, 18). All patients were seen
every 3 months during the randomized phase for laboratory and clinical assessment. In
addition, annual liver ultrasounds were obtained to screen for hepatocellular carcinoma
(HCC), and serum alpha-fetoprotein levels were obtained every 3 months. Clinical endpoints
for the study included an increase in the Child-Turcotte-Pugh (CTP) score to 7 on two
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separate occasions 3 months apart, variceal bleeding, ascites, spontaneous bacterial
peritonitis, hepatic encephalopathy, HCC, or death. For the subgroup of patients with
noncirrhotic fibrosis at baseline, histologic progression was defined as a ≥2-point increase in
the Ishak fibrosis score (12).
YKL-40 serum assay
Stored serum samples were tested for YKL-40 levels with a commercially available ELISA
kit (Metra YKL-40, Quidel, San Diego, CA) as described previously (Normal range: 24–125
ug/l) (14).
Testing for YKL-40 promoter polymorphisms
DNA was extracted at SeraCare from frozen whole blood. Genotyping for the single tag
nucleotide polymorphism (SNP) rs4950928 of the CHI3L1 promoter polymorphism
accounting for the upstream at −131G → C point mutation on genomic DNA was performed
with allele-specific real-time PCR at a high-throughput facility (Celera Diagnostics,
Alameda, CA). The YKL-40 genotypes were classified as CC homozygous for the major
allele, CT heterozygous, or TT homozygous for the minor allele. From prior publications
and HapMap data, we expected the distribution of YKL-40 genotypes in Caucasians and
African Americans to be similar. Therefore, in order to maximize power, we performed the
analyses in all of the patients grouped together but also performed all of the analyses in
Caucasians alone.
Statistical analyses
Log-transformation of non-normally distributed variables including serum YKL-40 levels
was undertaken when needed. Continuous variables are presented as means ± standard
deviation; we derived additive linear models for the number of minor alleles (including a
continuous variable for the number of minor alleles) to compare values by genotype (e.g.,
test of trend). To assess changes in serum YKL-40 values over time, we used random effects
models that were fit in SAS based on proc mixed that included a random effect of time as
well as the interaction of time with genotype (SAS Institute, Cary, NC, USA).
To predict the risk of clinical progression in liver disease by YKL-40 promoter
polymorphism, we used Cox proportional hazards regression, and data were censored at the
patient’s last follow-up visit or at 1,400 days (i.e., 3.8 years) after randomization, whichever
occurred first. To assess the relationship between histological progression and YKL-40
genotype, we relied upon complementary log-log regression analysis. All analyses were
performed at the Data Coordinating Center (New England Research Institutes, Watertown,
MA) with SAS statistical software version 9.2 (SAS Institute).
RESULTS
Lead-in analysis population
The baseline features of the 456 patients enrolled in the lead-in phase of the HALT-C Trial
who underwent genetic testing are provided in Table 1. Overall, 283 (68.0%) patients were
CC homozygous at the major allele, 123 were CT heterozygotes (29.6%), and 10 (2.4%)
were TT homozygotes. The CT and TT genotypes were in Hardy-Weinberg equilibrium (P =
0.43) in the overall study population as well as in the Caucasian subgroup (P = 0.48). In
addition, the 17% overall frequency of the T allele in these HALT-C Trial patients is similar
to that reported in other patient populations (10, 11).
The age, demographic features, and baseline laboratory markers of liver disease severity
were similar in the three YKL-40 genotype subgroups with the exception of race/ethnicity,
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serum ALT and BMI. Furthermore, the histological severity of liver disease was similar, as
was the proportion with esophageal varices, in all three subgroups. As expected, baseline
serum YKL-40 levels were significantly lower in the TT subjects compared to the CT or CC
subgroups (1.96 versus 2.25 versus 2.47, P <0.001, trend test). Having shown previously
that lower baseline serum YKL-40 levels were independently associated with week-20
virologic responses, we also examined the relationship between YKL-40 genotype and
week-20 virologic response. The likelihood of a week-20 virologic response was similar for
the CC and CT genotypes but somewhat higher for the TT group, although the difference
did not reach statistical significance (Table 1). In addition, baseline serum YKL-40 levels
differed according to subgroup with those in the TT subgroup being lowest (Table 1). Serum
YKL-40 levels also decreased significantly by week 24; however, the magnitude of decline
in serum YKL-40 levels did not differ according to subgroup (Figure 2A). In addition,
amongst the 158 patients in the responder arm who received a full 48-week course of
peginterferon and ribavirin, the likelihood of a week-48 and week-72 virologic response did
not differ by YKL-40 genotype (Data not shown). However, assessment of serial serum
YKL-40 levels amongst the 158 lead-in responders demonstrated a significant decline over
time and a difference in levels according to subgroup but the magnitude of decline in serum
YKL-40 levels did not differ according to subgroup (Figure 2B).
Randomized phase analysis
The mean age of the 462 HALT-C Trial subjects entering the randomized phase in this study
was 49.5 years; 70% were male, 71% were Caucasian, and 49% were randomized to receive
low-dose peginterferon (Table 2, Figure 1). Seven (1.7%) were TT minor allele
homozygotes, 119 (28.5%) were CT heterozygotes, and 292 (70.0%) were CC major allele
homozygotes. The distribution of YKL-40 genotypes was in Hardy-Weinberg equilibrium
overall (P = 0.19) and in the Caucasian-only subset (P = 0.24). Baseline demographics of the
three groups of patients were similar, with the exception that all of the TT homozygotes, but
not the other subgroups, were Caucasian. In addition, laboratory markers of disease severity
as well as baseline histological features were similar in the three groups except for higher
serum AST and ALT levels in the TT subgroup. Baseline serum YKL-40 levels, however,
were significantly lower in the TT subgroup compared to the CT and CC subgroups (2.20
versus 2.34 versus 2.50, P <0.001, trend test).
Clinical and histological outcomes
During a mean follow-up of 51 months, a primary clinical outcome developed in 69 (15%)
of the 462 randomized patients, including CTP increase (n = 40), HCC (n = 7), ascites (n =
32), encephalopathy (n = 15), variceal bleeding (n = 8), and death (n = 24). No significant
relationship emerged, however, between YKL-40 genotype and the risk of a clinical
outcome (Table 3). In addition, analyses conducted in patients stratified by treatment group
during the randomized phase failed to demonstrate an association of YKL-40 genotype with
clinical liver disease progression. Finally, analysis of the 1,050 randomized patients also
failed to demonstrate a significant association between YKL-40 genotype and risk of
developing a clinical outcome (See Supplemental Table 1). A worsening of hepatic fibrosis,
defined as an increase in the Ishak fibrosis score of ≥2 points at month 24 or 48 compared to
baseline, was a primary endpoint in the HALT-C Trial for patients with non-cirrhotic
fibrosis. Among the 280 patients with a pretreatment Ishak fibrosis score of <5, 209 had a
follow-up biopsy that was adequate for analysis, and, among these, 191 also had YKL-40
genetic data available. Among these 191 patients, 90 were randomized to maintenance
peginterferon while 101 were not treated. During follow-up, 70 (33.5%) patients had
worsening hepatic fibrosis, while 139 had stable or unchanged Ishak fibrosis scores, but the
distribution of YKL-40 genotypes was not significantly different in subjects with and
without histological progression (Table 4). In addition, an analysis of the 935 randomized
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HALT-C Trial patients with YKL-40 genetic data available showed, similarly, no
association with clinical outcomes nor with histological outcomes in 432 subjects with
paired biopsies (See supplemental Table 1). In addition, analyses stratified by treatment
group failed to demonstrate associations with YKL-40 genotype.
During the randomized phase of the trial, serum YKL-40 levels remained consistently lower
in subjects with the TT genotype than in subjects with the CT and CC genotypes (Figure 3).
In fitting a model of serial YKL-40 levels over time, we found that the YKL-40 genotype,
the baseline serum YKL-40 level, and the effect of time were all significant (all P <0.001).
No interaction was apparent, however, between YKL-40 genotype and serum YKL-40 levels
over time.
Discussion
Host, environmental, and genetic factors are thought to explain, in part, the highly variable
rate of hepatic fibrosis and clinical progression of liver disease in patients with CHC. Recent
studies based on exploratory genome-wide association methodologies have led to the
identification of a series of genes that may increase an individual patient’s risk of
progressing to advanced fibrosis and cirrhosis (19,20). In addition, hypothesis-driven genetic
association studies involving a limited number of polymorphisms in genes that are linked
biologically to hepatic fibrogenesis have been reported, but their results have not been
validated consistently in independent cohorts (21,22). Hepatic YKL-40 mRNA levels
correlated strongly with serum YKL-40 levels in a prospective study of 87 untreated patients
with CHC that were followed prospectively over 10 years (1). In addition, recent reports
demonstrated that a functional polymorphism in the promoter region of the YKL-40 gene
was associated with reduced serum YKL-40 levels in multiple independent patient
populations and with reduced gene expression in peripheral blood cells (10,11,23).
Furthermore, based upon both qualitative and quantitative genetic analyses, Berres et al (11)
showed that, in patients with CHC, histological fibrosis scores and serum YKL-40 levels
were associated after adjustment for other co-factors with YKL-40 promoter
polymorphisms. Having obtained extensive serum YKL-40 data in a large group of well
characterized patients with CHC enrolled in the HALT-C Trial, we sought to determine
whether significant associations existed between YKL-40 promoter polymorphisms and
serum YKL-40 levels as well as with baseline liver-disease severity, response to antiviral
therapy, and clinical and histological progression of liver disease (14, 15).
The distribution of YKL-40 promoter polymorphisms in the HALT-C Trial patients was
similar to that reported in HapMap general population controls as well as in another large
study of patients with asthma (10). These data suggest that, contrary to the findings of
Berres et al (11), YKL-40 promoter polymorphisms are not protective against the
development of advanced liver fibrosis. However, other host and environmental co-factors
for fibrosis progression that were present in many HALT-C Trial patients—e.g., history of
heavy alcohol consumption, increased body mass index, and diabetes mellitus—may have
overshadowed the protective effect of a YKL-40 promoter polymorphism (TT) associated
with lower serum YKL-40 levels. In addition, the limited number of patients with the
favorable genotype (TT) as well as the selection of patients with advanced fibrosis for entry
into the HALT-C Trial may have precluded the detection of an association between YKL-40
genotype and baseline disease severity. Furthermore, the presence of advanced liver fibrosis
in and of itself may have reduced the clearance of YKL-40 from the circulation, leading to
spuriously high serum levels even in patients with the TT genotype. In support of these
concepts, the study by Berres et al (11) included patients with CHC who had a broader
distribution of fibrosis scores, ranging from normal (stage 0) to cirrhosis (stage 6), as
compared to the more limited distribution of fibrosis states in the current study (confined to
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Ishak stages 3–6); in addition, none of the patients included in the study by Berres et al (11)
were reported to have consumed excessive amounts of alcohol, while many HALT-C Trial
subjects, although abstinent at trial entry, had a history of high-level lifetime alcohol use.
Furthermore, the previously reported association between serum YKL-40 levels and
YKL-40 genotype was restricted to patients with mild hepatic fibrosis (11), presumably
because advanced hepatic fibrosis can result in reduced clearance of YKL-40 and other
serum fibrosis markers. A significant association between baseline serum YKL-40 levels
and YKL-40 genotype was observed in the 456 patients entering the lead-in phase as well as
the 462 randomized HALT-C Trial patients (Tables 1 and 2). The persistence of low serum
YKL-40 levels over time in the lead-in patients with genotype TT compared to those with
genotype TC and CC also suggests the presence of a strong and persistent association
between YKL-40 genotype and circulating levels of YKL-40 (Figure 2).
In addition to pursuing associations between YKL-40 promoter polymorphisms and liver-
disease progression, we explored the potential role of YKL-40 promoter polymorphisms in
predicting the outcomes of antiviral therapy. Multiple recent reports have demonstrated the
importance of interleukin-28B (IL28B) gene polymorphisms in predicting the likelihood of
achieving viral suppression during and after peginterferon and ribavirin therapy in
treatment-naïve patients with CHC (24,25). In addition, a prior analysis of HALT-C Trial
patients demonstrated that the same IL28B polymorphisms are associated significantly with
the likelihood of achieving a week-20 virological response as well as an SVR following 48
weeks of therapy (26). In the current study, we did not find a significant association of the
YKL-40 genetic polymorphisms with week-20 (on treatment response), week-48 (end-of-
treatment response), or week-72 (SVR) virological responses. In addition, when we
analyzed YKL-40 polymorphisms in the entire cohort of 935 HALT-C Trial lead-in patients
with available genetic data (n = 675 Caucasian), we did not see an association between this
genetic marker and virological response (data not shown). Therefore, our prior observations
that baseline serum YKL-40 levels are an independent predictor of virological response
during the lead-in phase of the HALT-C Trial may reflect the association of lower serum
YKL-40 levels with less severe liver disease, which is known to influence virological
responsiveness (15,16). Nonetheless, studies of YKL-40 genotype in treatment-naïve
patients with CHC may be worthwhile in HCV-infected patients with a broader distribution
of disease severity.
We also explored the relationship between YKL-40 promoter polymorphisms and the risk of
clinical and histological liver-disease progression over time in a large cohort of well
characterized and prospectively monitored patients with CHC. In the current HALT-C Trial
subset, however, we observed no significant association between YKL-40 genotype and the
risk of clinical or histological liver disease progression (Tables 3 and 4). When we also
analyzed YKL-40 genotype in a larger cohort of 935 randomized HALT-C Trial patients
who had available genetic data, we also failed to find an association of YKL-40
polymorphisms with clinical and histological disease progression (Supplementary Table 1).
Nonetheless, serum YKL-40 levels remained significantly lower throughout follow-up
monitoring in subjects with the TT genotype compared to subjects with the CT and CC
genotypes (Figure 3). Because we showed previously that baseline serum YKL-40 levels are
associated with the risk of liver-disease progression, our current data suggest that serial
measurements of serum YKL-40 levels, not YKL-40 gene polymorphisms, may prove to be
a useful prognostic marker in patients with CHC and advanced fibrosis. Our study findings
are consistent with other analyses of the HALT-C Trial cohort that also failed to
demonstrate a genetic predisposition to clinical or histologic progression of liver disease
over time (27,28). Absence of an association may have resulted, in part, from the selection
of a cohort of patients with advanced fibrosis for inclusion in the HALT-C Trial. In support
of this notion, recent reports demonstrate that a panel of seven genetic polymorphisms,
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“CRS-7,” is associated with the risk of fibrosis progression in patients with mild CHC but is
less useful in patients with more advanced fibrosis (29,30).
In conclusion, our study results failed to support a reduced frequency of the YKL-40
promoter polymorphism associated with reduced serum YKL-40 levels in our population of
patients with CHC and advanced fibrosis. This observation suggests that the previously
reported association of the YKL-40 promoter polymorphism with liver disease severity (11)
is most useful in patients with CHC who lack other risk factors or environmental co-factors
for advanced fibrosis. Our prior observation that lower baseline serum YKL-40 levels were
associated with improved responsiveness to peginterferon and ribavirin was probably
secondary to an association of baseline liver-disease severity with serum YKL-40 levels,
rather than to an association with YKL-40 gene expression per se. Absence of an association
between YKL-40 promoter polymorphisms and the risk of clinical and histologic liver-
disease progression also suggests that this locus may be more important in the initiation and/
or development of early fibrosis than in the progression of more advanced, established liver
fibrosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of study population
There were 456 patients with CHC and advanced fibrosis who were retreated with
peginterferon-α2a/ribavirin for 24 weeks during the “Lead-in” phase of the HALT-C Trial
included in the current study. Two-hundred and eighty eight patients who failed to clear
HCV RNA at week 20 entered the randomized phase while 63 patients who had a
virological relapse/breakthrough after 24 to 48 weeks of peginterferon/ribavirin therapy also
entered the randomized phase. Finally, there were 111 “Express” patients who had received
peginterferon/ribavirin therapy and entered the randomized phase. All of the subjects were
followed for clinical and histological liver disease progression through a median follow-up
of 3.8 years.
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Figure 2. Serum YKL-40 levels and YKL-40 genotype in the lead-in/responder arm of HALT-C
A) The baseline serum YKL-40 levels were significantly lower in patients with the TT
genotype compared to those with the CT and CC genotype (p < 0.001). In addition, the
serum YKL-40 levels significantly decreased by week 24 (p< 0.001) and remained
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significantly lower in the subjects with the TT genotype compared to those with the CT and
CC genotype (p < 0.001). B) In the 158 subjects with a virological response during the lead-
in phase who received a full 48 week course of peginterferon and ribavirin, the serum
YKL-40 levels significantly decreased over time (p< 0.001) and remained significantly
lower in the subjects with the TT genotype compared to those with the CT and CC genotype
(p < 0.001).
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Figure 3. Serum YKL-40 levels stratified by YKL-40 genotype during the randomized phase of
the HALT-C Trial
At baseline, the serum YKL-40 levels were significantly lower in subjects with the TT
minor allele compared to the CT heterozygotes and CC homozygotes (p < 0.0001). Although
the serum YKL-40 levels significantly increased in each subgroup over time (p < 0.0001)
they remained consistently lower in the CC subgroup compared to the others (P < 0.001).
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